Literature DB >> 29938337

Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation.

Itay Lotan1,2, Judith Brody3,4, Mark Andrew Hellmann3,5, Omer Bialer3,4, Esther Ganelin-Cohen3,6, Natalia Michaeli3,7, Romain Marignier8, Hadas Stiebel-Kalish3,4.   

Abstract

Optic neuritis (ON) is a common clinical manifestation in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease. Other clinical manifestations include acute demyelinating encephalomyelitis, transverse myelitis and neuromyelitis optica spectrum disorders. Uncommon presentations of MOG-positive disease have recently been reported. ON in MOG-positive disease commonly involves the anterior portion of both optic nerves, leading to bilateral disc swelling. During the early stages of ON, in the setting of bilateral disc swelling and pain, patients may initially be suspected as pseudotumor cerebri (PTC). In this study, we report five cases presenting early in the course of MOG-IgG-related ON, which were misdiagnosed as PTC in the emergency department. MOG-IgG-positive ON requires timely treatment to prevent RNFL and vision loss secondary to the high relapse rate associated with these antibodies. Our aim is to increase the awareness of the unique findings of MOG-IgG-positive ON, which may initially mimic PTC, thereby delaying treatment.

Entities:  

Keywords:  MOG antibodies; Optic neuritis; Pseudotumor cerebri

Mesh:

Substances:

Year:  2018        PMID: 29938337     DOI: 10.1007/s00415-018-8956-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.

Authors:  Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

2.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

3.  Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.

Authors:  Sudarshini Ramanathan; Kristina Prelog; Elizabeth H Barnes; Esther M Tantsis; Stephen W Reddel; Andrew P D Henderson; Steve Vucic; Mark P Gorman; Leslie A Benson; Gulay Alper; Catherine J Riney; Michael Barnett; John D E Parratt; Todd A Hardy; Richard J Leventer; Vera Merheb; Margherita Nosadini; Victor S C Fung; Fabienne Brilot; Russell C Dale
Journal:  Mult Scler       Date:  2015-07-10       Impact factor: 6.312

4.  Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

Authors:  Joanna Kitley; Patrick Waters; Mark Woodhall; M Isabel Leite; Andrew Murchison; Jithin George; Wilhelm Küker; Saleel Chandratre; Angela Vincent; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

5.  Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.

Authors:  Deborah I Friedman; Grant T Liu; Kathleen B Digre
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

6.  Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

Authors:  Joanna Kitley; Mark Woodhall; Patrick Waters; M Isabel Leite; Emma Devenney; John Craig; Jacqueline Palace; Angela Vincent
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

Review 7.  Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.

Authors:  Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Autoimmun Rev       Date:  2015-12-17       Impact factor: 9.754

Review 8.  Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Authors:  Scott S Zamvil; Anthony J Slavin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-01-22

9.  Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis.

Authors:  Konstantina Chalmoukou; Harry Alexopoulos; Sofia Akrivou; Panos Stathopoulos; Markus Reindl; Marinos C Dalakas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-02

10.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.

Authors:  Florence Pache; Hanna Zimmermann; Janine Mikolajczak; Sophie Schumacher; Anna Lacheta; Frederike C Oertel; Judith Bellmann-Strobl; Sven Jarius; Brigitte Wildemann; Markus Reindl; Amy Waldman; Kerstin Soelberg; Nasrin Asgari; Marius Ringelstein; Orhan Aktas; Nikolai Gross; Mathias Buttmann; Thomas Ach; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt
Journal:  J Neuroinflammation       Date:  2016-11-01       Impact factor: 8.322

View more
  2 in total

1.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension: A Case Report.

Authors:  Jaydip Ray Chaudhuri; Jui Jade Bagul; Alluri Swathi; Bhim Sen Singhal; N Chakradhar Reddy; Kiran Kumar Vallam
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-10-19

2.  Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination.

Authors:  Lina Jeantin; Adèle Hesters; Dorine Fournier; Bénédicte Lebrun-Vignes; Aurélie Méneret; Caroline Papeix; Valérie Touitou; Elisabeth Maillart
Journal:  J Neurol       Date:  2022-04-23       Impact factor: 6.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.